HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITORY ANTIBODY FORMULATIONS, KITS, AND METHODS OF TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME

1 . A method of treating a subject suffering from plasma therapy resistant aHUS comprising administering to the subject an effective amount of an anti-MASP-2 antibody, or antigen binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO:2 and (ii) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO:3; wherein the method comprises an administration cycle comprising an induction phase and a maintenance phase, wherein:

(a) the induction phase comprises a period of one week, wherein the anti-MASP-2 antibody, or antigen-binding fragment thereof, is administered at a dose of about 370 mg on Day 1 and on Day 4; and

(b) the maintenance phase comprises a period of at least 26 weeks, commencing on Day 1 of the induction period, wherein the anti-MASP-2 antibody, or antigen-binding fragment thereof, is administered at a daily dose of about 150 mg.

2 . The method of claim 1 , wherein the anti-MASP-2 antibody is administered intravenously in a solution suitable for intravenous delivery during the induction period.

3 . The method of claim 1 , wherein the anti-MASP-2 antibody is administered subcutaneously during the maintenance period.

4 . The method of any of claims 1-3 , wherein the maintenance phase comprises or consists of 26 weeks.

5 . The method of any of claims 1-3 , wherein the maintenance period lasts longer than 26 weeks (6 months).

6 . The method of any of claims 1-3 , wherein the maintenance period lasts from at least 6 months up to 2 years.

7 . The method of claim 2 , wherein the anti-MASP-2 antibody, or antigen-binding fragment thereof, is administered intravenously to the subject during the induction period at a dose of about 370 mg on Day 1 and on Day 4.

8 . The method of claim 3 , wherein the method comprises administering subcutaneously to a subject suffering from aHUS a daily dosage of about 150 mg for a time period of at least 26 weeks, a stable pharmaceutical formulation suitable for parenteral administration to a mammalian subject, comprising: (a) an aqueous solution comprising a buffer system having a pH of 5.0 to 7.0; and (b) the monoclonal antibody or fragment thereof that specifically binds to human MASP-2 at a concentration of about 50 mg/mL to about 250 mg/mL; wherein the formulation has a viscosity of between 2 and 50 centipoise (cP), and wherein the formulation is stable when stored at between 2° C. and 8° C. for at least six months.

9 . The method of claim 3 , wherein the method comprises administering subcutaneously to a subject suffering from aHUS a daily dosage of about 150 mg for a time period of at least 26 weeks, a stable pharmaceutical formulation comprising 185 mg/mL of the monoclonal antibody, pH 5.8, citrate (20 mM), arginine (200 mM) and polysorbate 80 (0.01%).

10 . The method of claim 3 , wherein the SC administration is via an injection.

11 . The method of claim 10 , wherein the injection is carried out with a syringe having a 27G thin-walled needle.

12 . The method of claim 2 , wherein the intravenous solution comprising the anti-MASP-2 antibody is generated by combining an appropriate amount of a stable pharmaceutical formulation comprising 185 mg/mL of the monoclonal antibody, pH 5.8, citrate (20 mM), arginine (200 mM) and polysorbate 80 (0.01%)) with a pharmaceutically acceptable diluent prior to administration.

13 . The method of claim 10 , wherein the formulation comprises:

(a) polysorbate 80 at a concentration from about 0.01 to about 0.08% w/v;

(b) L-arginine HCl at a concentration from about 150 mM to about 200 mM;

(c) sodium citrate at a concentration from about 10 mM to about 50 mM; and

(d) about 150 mg/mL to about 200 mg/mL of the antibody.

14 . The method of claim 5 , wherein the maintenance phase last for a time period selected from the group consisting of: at least 39 weeks (9 months); at least 52 weeks (12 months); at least 78 weeks (18 months) and at least 104 weeks (24 months).